Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

Authors not listed

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2001

Abstract

The purpose of this study is to evaluate the safety and effectiveness of a once daily controlled-release form of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-10 MST

Cite this

APA
Anonymous. (2001). Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation. <em>Johnson & Johnson Pharmaceutical Research & Development, L.L.C.</em>. https://clinicaltrials.gov/study/NCT00253214
Vancouver
Anonymous. Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation. Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 2001.
BibTeX
@misc{anon2001Placeb, title = {Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation}, author = {Anonymous}, journal = {Johnson & Johnson Pharmaceutical Research & Development, L.L.C.}, year = {2001}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings